BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27491374)

  • 21. Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.
    Rodríguez Laval V; Pavel M; Steffen IG; Baur AD; Dilz LM; Fischer C; Detjen K; Prasad V; Pascher A; Geisel D; Denecke T
    Neuroendocrinology; 2018; 106(2):139-147. PubMed ID: 28384635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study.
    de Mestier L; Savagner F; Brixi H; Do Cao C; Dominguez-Tinajero S; Roquin G; Goichot B; Hentic O; Dubreuil O; Hautefeuille V; Walter T; Cadiot G
    J Clin Endocrinol Metab; 2021 Mar; 106(4):e1673-e1682. PubMed ID: 33382891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report.
    Søndenaa K; Sen J; Heinle F; Fjetland L; Gudlaugsson E; Syversen U
    World J Surg; 2004 Sep; 28(9):890-5. PubMed ID: 15593463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids.
    Manfé AZ; Norberto L; Marchesini M; Lumachi F
    In Vivo; 2011; 25(6):1027-9. PubMed ID: 22021701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary 5-HIAA excretion is not increased in patients with head and neck paragangliomas.
    van Hulsteijn LT; van Duinen N; Romijn JA; Smit JW; Corssmit EP
    Int J Biol Markers; 2012 Jul; 27(2):e160-3. PubMed ID: 22653742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
    Sen Gupta P; Grozinsky-Glasberg S; Drake WM; Akker SA; Perry L; Grossman AB; Druce MR
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):246-52. PubMed ID: 23790044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Factors for Survival among Patients with Small Bowel Neuroendocrine Tumours Associated with Mesenteric Desmoplasia.
    Laskaratos FM; Diamantopoulos L; Walker M; Walton H; Khalifa M; El-Khouly F; Koffas A; Demetriou G; Caplin M; Toumpanakis C; Mandair D
    Neuroendocrinology; 2018; 106(4):366-380. PubMed ID: 29320779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
    Bajetta E; Ferrari L; Martinetti A; Celio L; Procopio G; Artale S; Zilembo N; Di Bartolomeo M; Seregni E; Bombardieri E
    Cancer; 1999 Sep; 86(5):858-65. PubMed ID: 10463986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
    Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and predictive biomarkers in neuroendocrine tumours.
    Chan DL; Clarke SJ; Diakos CI; Roach PJ; Bailey DL; Singh S; Pavlakis N
    Crit Rev Oncol Hematol; 2017 May; 113():268-282. PubMed ID: 28427516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pitfalls in the diagnosis of carcinoids in patients treated with aminosalicylates].
    Dastych M; Dastych M; Zboril V; Senkyrík M; Starý K; Cáslavský J; Chmelík J
    Vnitr Lek; 2003 Mar; 49(3):200-4. PubMed ID: 12733495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors.
    Zuetenhorst JM; Korse CM; Bonfrer JM; Peter E; Lamers CB; Taal BG
    Clin Chem; 2004 Sep; 50(9):1634-9. PubMed ID: 15247155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients.
    van Dijk SC; de Herder WW; Kwekkeboom DJ; Zillikens MC; Feelders RA; van Schaik RH; van Driel M; van Leeuwen JP
    Bone; 2012 Jun; 50(6):1260-5. PubMed ID: 22425693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carcinoid tumors--somatostatine in the diagnosis and therapy.
    Kinova S; Duris I; Kratochvilova E; Ondrejka P; Payer J
    Bratisl Lek Listy; 2002; 103(3):108-12. PubMed ID: 12190042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
    Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
    QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid.
    Lionetto L; Lostia AM; Stigliano A; Cardelli P; Simmaco M
    Clin Chim Acta; 2008 Dec; 398(1-2):53-6. PubMed ID: 18760269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.